Brown Advisory’s Royalty Pharma RPRX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$555K Buy
9,903
+482
+5% +$25.1K ﹤0.01% 1106
2026
Q1
$452K Sell
9,421
-266
-3% -$11.7K ﹤0.01% 1089
2025
Q4
$374K Buy
+9,687
New +$369K ﹤0.01% 1148
2020
Q3
Sell
-11,082
Closed -$538K 994
2020
Q2
$538K Buy
+11,082
New +$549K ﹤0.01% 714

Other funds holding RPRX

Brown Advisory's RPRX Position: Q2 2026 in Review

Brown Advisory increased its Royalty Pharma (RPRX) stake by 5.1% in Q2 2026, buying an estimated $25.1K and bringing the position to 9,903 shares worth $555K. The position accounts for ﹤0.01% of the portfolio, ranked #1106.

Brown Advisory first reported a position in RPRX in Q2 2020 and has held it in 4 quarters since. 645 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

  • Brown Advisory held 9,903 shares of Royalty Pharma worth $555K as of Q2 2026.
  • Brown Advisory bought 482 Royalty Pharma shares in Q2 2026, an estimated $25.1K.
  • Royalty Pharma made up ﹤0.01% of Brown Advisory's portfolio in Q2 2026, its #1106 holding.
  • Brown Advisory first reported a position in Royalty Pharma in Q2 2020 and has held it in 4 quarters since.
  • 645 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Brown Advisory's 13F filing for Q2 2026, filed 14 Aug 2026.